ClinicalTrials.gg
Active, not recruitingNCT05006976NSACUpdated Apr 13, 2026

A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study

An interventional study of NSAC health only and NSAC health + MBW in Musculoskeletal Disorder, Anxiety Disorders and Depression, sponsored by Nordlandssykehuset HF. Active, not recruiting at 5 sites in Norway. Open to participants aged 23 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Nordlandssykehuset HF · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,180
Allocation
Randomized
Ages
23 Years and older
Sex
All
01

Study summary

The Norwegian Sickness Absence Clinic (NSAC) Nudge Study is a naturalistic randomized controlled multicentre trial which aim is to measure the efficacy of nudging clinicians' attention towards patients' motivation for work, barriers for return to work and work environment challenges, on functional recovery as primary outcome, and health outcomes as secondary outcome.

Patients will be recruited in five different NSACs across northern Norway. In total 1100 patients will be randomized to two equal probability treatment arms: 1) NSAC with the nudge, and 2) NSAC without the nudge. The nudge is tailored to the individual patient's needs using survey, and the clinicians are presented with a summary of this patient survey prior to consultations highlighting health problems and challenges as reported by the patient in the survey.

Read the detailed description

The NSAC Nudge Study is part of a broader project, the Norwegian Sickness Absence Clinic Study (NSACS). The NSACS has two sources of funding (Northern Norway Regional Health Authority and The Norwegian Labour and Welfare Administration (NAV)), and involves two RCTs (NSAC Nudge and NSAC Efficacy) and fifteen work packages covering aspects of efficacy, interactions in efficacy, scalability, health economics, and characteristics of the target group and the patient group. The randomized controlled trial (RCT) NSAC Nudge is the subject of this trial registration. A list of the associated work-packages (WPs) is available in the protocol attached this registration at a later time point.

The NSAC Nudge Study is a randomized controlled multicentre trial, carried out in northern Norway and involving 5 Norwegian Sickness Absence Clinics (NSAC [Helse i Arbeid]). The study will recruit 1100 patients, randomized in equal proportions to either of two treatment arms 1) Treatment at the NSAC following a patient survey of health problems and 2) treatment at the NSAC following a patient survey of health problems as well as a survey on motivation for work, barriers for return to work and work environment (MBW).

The NSACs are staffed by teams of medical doctors specializing in physical medicine and rehabilitation, psychologists, physiotherapists and employment support supervisors. The NSAC service aims to provide quick clarification of health problems or treatment to patients with common mental disorders or musculoskeletal health problems with the goals of functional improvement, prevention of long-term sickness absence and return to work.

All patients are asked to fill out an online survey about their health and MBW factors between time of referral and their first treatment. The survey will also handle randomization. The NSAC clinicians are given a summary to be used in the treatment of the individual patient, and the effect of this comprehensive mapping and the provision of a condensed report to clinician prior to consultation is the primary aim of the RCT. The clinicians will be trained in how providing this information is going to guide clinical practice and using this information in treatment of patients.

The anticipated mechanism of the nudge is 1) an increased expectation among patients that MBW factors will be addressed during treatment, and/or 2) an increased focus on MBW factors by clinician in treatment, both due to the report and the patients' expectations. Whether this mechanism has an effect on patients' return to work (RTW) outcomes, prevention of sickness absence and general alleviation of symptoms will also be explored.

The data necessary to answer the research questions are gathered from national registries via personal identifier, registry data on population level, questionnaires filled out by the patient (data on health and working conditions) and questionnaires filled out by the clinician after each consultation (data on number of treatments, diagnosis, professions involved and types of treatment provided).

The patient questionnaire is divided in two surveys; 1) a health survey and 2) a survey on health and MBW. The health survey covers health, and includes musculoskeletal problems, mental health and other health related issues (such as alcohol consumption, medication and physical activity). The MBW survey includes working conditions (including inter alia questions on social support, work/family conflict and bullying), barriers for RTW, labour market affiliation, other personal aspects (such as demography and motivation for work), questionnaires for health economic evaluation and expectations for treatment.

By and large the questionnaire consists of test batteries which have been validated for specific topics. In an effort to reduce the number of questions posed to each patient, the baseline questionnaire will employ index questions which have proven psychometric properties in terms of factor loading or similar, meaning that if a problem on a specific topic such as neck pain is not indicated, the patient will not be presented with the Neck Disability Index questionnaire. The patient questionnaires will be filled out electronically after referral and prior to first treatment (Baseline, Time 0), as well as at 6 months after baseline (Time 1). We planned for a 12-month follow-up survey, but because of a technical error this second survey was never sent to participants. Accordingly the second follow-up survey will be sent to participants ultimo June 2024, which is in the interval between 17- and 31 months (depending on date of recruitment) after time of baseline survey (Time 2).

In the NSAC Nudge Study, receiving treatment at NSAC (Norwegian name HiA) does not presuppose consent to participate in research, but a mapping of health status is nevertheless a mandatory part of treatment. However, participation in research requires sharing these data and access to registry-based data for the involved patients.

02

Conditions studied

  • Musculoskeletal Disorder
  • Anxiety Disorders
  • Depression
  • Fatigue
  • Pain
  • Occupational Exposure
  • Work Related Stress
  • Workplace Bullying
  • Employment
  • Sickness Absence
  • Return to Work

Keywords

  • Return to work
  • Sickness absence
  • Nudge
  • Barriers for return to work
  • Motivation for work
  • Demand and control
  • Work/family conflict
  • Bullying
03

In context

Musculoskeletal Diseases

753 studies on the registry are indexed under Musculoskeletal Diseases; 164 are open to participants now.

This study's enrollment of 1,180 is above the median of 76 across 519 interventional studies indexed under Musculoskeletal Diseases.

Browse Musculoskeletal Diseases studies →

Lead sponsor

Nordlandssykehuset HF is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
23 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For the study, the single inclusion criteria is that the patient is offered a consultation or treatment at the NSAC (Norwegian: HiA).

Exclusion criteria

Exclusion Criteria:

  • Aged younger than 23 years at time of referral. The NSACs have guidelines that describe eligibility for treatment, and excludes patients that are either too healthy for the measure, too sick for the measure, not relevant diagnosis or otherwise not considered being in the target group for the measure.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,180 participants (actual)

Study arms

  • Active comparator
    NSAC health only

    Treatment as usual (TAU) at NSAC, following a digital survey of health problems and the provision of a condensed report of this survey to clinician prior to consultation.

    Other: NSAC health only

  • Experimental
    NSAC health + MBW

    Treatment as usual (TAU) at NSAC, following a digital survey of health problems as well as Motivation, Barriers for return to work and Work environment (MBW), and the provision of a condensed report of this survey to clinician prior to consultation.

    Other: NSAC health + MBW

Interventions

  • OtherNSAC health only

    NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In "NSAC health only", clinicians are provided survey information on potential health problems only.

  • OtherNSAC health + MBW

    NSAC is an outpatient service delivered under the auspices of the specialist health care sector to patients currently on sick leave or at risk for long-term sickness absence. The service is staffed by medical doctors specialising in musculoskeletal health, physiotherapists, psychologists and welfare sector counsellors, and aims to provide patients with multi-disciplinary treatment with the intent of functional recovery. In "NSAC health + MBW" clinicians are provided survey information on potential health problems as well as information on motivation for work, barriers for return to work and work environment factors.

06

What researchers measure

Primary outcomes

  1. Functional recovery: status, plan and prognosis for employment versus sickness absence

    Clinician report at last consultation of current status, plan and prognosis for patient employment versus sickness absence. Status is current employment versus sickness absence, plan refers to patients own ambition and plans for employment versus sickness absence short term, while prognosis refers to the clinicians assessment of prognosis for employment versus sickness absence in 12 months.

    Time frame: At last appointment at NSAC (can vary substantially between patients, but generally < 3 months after first appointment at NSAC)

  2. Functional recovery: sickness absence self-report

    Employment, sickness absence and application for rehabilitation benefits between Time 0 and Time 2, based on patient self-report.

    Time frame: Up to 31 months post baseline survey

  3. Functional recovery: sickness absence registry data

    Employment, sickness absence and application for rehabilitation benefits during first 365 days post baseline survey, based on registry data.

    Time frame: 12 months post baseline survey

  4. Functional recovery: disability benefits

    Employment, sickness absence, rehabilitation benefits and disability benefits during 5-year period post baseline survey, all based on registry data.

    Time frame: 60 months post baseline survey

Secondary outcomes

  1. Mental health

    Changes in self-reported mental health between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Hopkins Symptoms Checklist - 10 (HSCL-10).

    Time frame: Up to 31 months post baseline survey

  2. Anxiety

    Changes in self-reported anxiety between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Beck Anxiety Inventory (BAI). The instrument is provided to patients upon indication, defined as a HSCL-10 score \> 1.4

    Time frame: Up to 31 months post baseline survey

  3. Depressive symptoms

    Changes in self-reported depression between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Beck Depression Inventory (BDI). The instrument is provided to patients upon indication, defined as a HSCL-10 score \> 1.4

    Time frame: Up to 31 months post baseline survey

  4. Sleep

    Changes in self-reported sleep between Time 0 and Time 1, and between Time 0 and Time 2, measured using 3 questions commonly used to diagnose sleeping disorder according to the DSM-IV criteria for insomnia.

    Time frame: Up to 31 months post baseline survey

  5. Health Anxiety

    Changes in self-reported health anxiety between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Whitely Index. All patients are asked the first question in the test battery, and the entire instrument is provided to patients with a score of \>3 on this question

    Time frame: Up to 31 months post baseline survey

  6. Subjective health complaints

    Changes in subjective health between Time 0 and Time 1, and between Time 0 and Time 2, measured using a modified version of the Ursin Health Inventory.

    Time frame: Up to 31 months post baseline survey

  7. Back pain

    Changes in self-reported back pain Time 0 and Time 1, and between Time 0 and Time 2, measured using the Oswestry Disability Index (ODI). All patients are asked whether they suffer from musculoskeletal pain, and if present, they are provided questions on localization of pain. In case of back pain, patients are provided the ODI.

    Time frame: Up to 31 months post baseline survey

  8. Neck pain

    Changes in self-reported neck pain between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Neck Disability Index (NDI). All patients are asked whether they suffer from musculoskeletal pain, and if present, they are provided questions on localization of pain. In case of neck pain, patients are provided the NDI.

    Time frame: Up to 31 months post baseline survey

  9. Pain intensity

    Changes in self-reported pain intensity between Time 0 and Time 1, and between Time 0 and Time 2, measured using a visual analogue scale scored between 0 and 10. All patients are asked whether they suffer from musculoskeletal pain, and if present, they are provided questions on pain intensity during rest and activity.

    Time frame: Up to 31 months post baseline survey

  10. Fear avoidance

    Changes in self-reported fear avoidance between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Fear Avoidance Beliefs Questionnaire (FABQ). All patients are asked whether they suffer from musculoskeletal pain, and if present, they are provided the FABQ.

    Time frame: Up to 31 months post baseline survey

  11. Physical activity

    Changes in self-reported level of physical between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Saltin-Grimby Physical Activity Level Scale (SGPALS).

    Time frame: Up to 31 months post baseline survey

  12. Fatigue

    Changes in self-reported fatigue between Time 0 and Time 1, and between Time 0 and Time 2, measured using the Fatigue Assessment Scale. All patients are asked the first question in the test battery, and the entire instrument is provided to patients with a score of ≥ 3 on this question

    Time frame: Up to 31 months post baseline survey

  13. Pain localization

    Changes in self-reported localization of pain between Time 0 and Time 1, and between Time 0 and Time 2. All patients are asked whether they suffer from musculoskeletal pain, and if present, they are provided questions on localization of pain.

    Time frame: Up to 31 months post baseline survey

  14. Cause of pain

    Changes in self-reported cause of pain between Time 0 and Time 1, and between Time 0 and Time 2. All patients are asked whether they suffer from musculoskeletal pain, and if present, they are provided questions on the believed cause of pain.

    Time frame: Up to 31 months post baseline survey

  15. Self-reported diagnoses

    Changes in self-reported diagnoses between Time 0 and Time 1, and between Time 0 and Time 2. The respondent is asked whether he/she thinks they have Covid-19 sequelae, myalgic encephalomyelitis/chronic fatigue syndrome, whiplash, fibromyalgia, hypermobility, irritable bowel syndrome or food intolerance, or whether they have been diagnosed with either of these by health personnel.

    Time frame: Up to 31 months post baseline survey

Other outcomes

  1. Preventive effect of sickness absence

    Changes in self-reported beliefs about the potential preventive effect of short-term sickness absence on long term sickness absence between Time 0 and Time 1, and between Time 0 and Time 2. The respondent is asked whether he/she agrees to 5 different statements on this topic, using a 5-point likert scale.

    Time frame: Up to 31 months post baseline survey

  2. Health economic evaluation: self report

    Health economic evaluation is measured using the EQ-5D and the ReQol instruments, issued to patients at baseline (Time 0) and at Time 1 and Time 2, to assess change.

    Time frame: Up to 31 months post baseline survey

  3. Health economic evaluation: labour costs

    Health economic evaluation also involves data on number of professions seeing the patient and number of working hours spent on the patient by each profession seeing the patient during the treatment period, recorded in questionnaires filled out by the clinicians after each consultation. This enables calculation of costs in terms of manpower and staff.

    Time frame: 12 months post baseline survey

  4. Expectations to- and evaluation of treatment

    Using open-ended questions, patients are asked about their expectations towards treatment prior to first treatment, and about their evaluation of treatment 6- and 12 months first treatment. These two will be compared.

    Time frame: Up to 31 months post baseline survey

  5. Barriers for return to work

    Changes in self-reported barriers for return to work between Time 0 and Time 1, and between Time 0 and Time 2. The questionnaire includes 26 items concerning barriers for return to work and is part of the survey in the MBW intervention.

    Time frame: Up to 31 months post baseline survey

  6. Motivation for work

    Changes in self-reported motivation for work between Time 0 and Time 1, and between Time 0 and Time 2. The questionnaire consists of a number of questions concerning motivation, and is part of the survey in the MBW intervention.

    Time frame: Up to 31 months post baseline survey

  7. Effort/reward imbalance

    Changes in self-reported effort/reward imbalance between Time 0 and Time 1, and between Time 0 and Time 2. Effort/reward imbalance is part of the survey in the MBW intervention, and is measured using the 3 items with the highest factor loading in the Siegrist Effort/Reward Imbalance Questionnaire (short version). A high score on either of the three items triggers the rest of the questionnaire.

    Time frame: Up to 31 months post baseline survey

  8. Workplace bullying

    Changes in self-reported workplace bullying between Time 0 and Time 1, and between Time 0 and Time 2. Workplace bullying is measured using the Short Negative Acts Questionnaire (SNAQ).

    Time frame: Up to 31 months post baseline survey

  9. Economic situation

    Changes in self-reported economic situation between Time 0 and Time 1, and between Time 0 and Time 2. The questionnaire includes 2 items concerning economic problems and concerns about economic problems.

    Time frame: Up to 31 months post baseline survey

  10. Procedural justice

    Changes in self-reported procedural justice between Time 0 and Time 1, and between Time 0 and Time 2. Procedural justice is part of the survey in the MBW intervention, and is measured by 3 items concerning workplace decisions.

    Time frame: Up to 31 months post baseline survey

  11. Relational justice

    Changes in self-reported relational justice between Time 0 and Time 1, and between Time 0 and Time 2. Relational justice is part of the survey in the MBW intervention, and is measured by 4 items concerning the general behaviour of the respondent's supervisor.

    Time frame: Up to 31 months post baseline survey

  12. Job phobia

    Changes in self-reported job phobias between Time 0 and Time 1, and between Time 0 and Time 2. Job phobia is measured by 12 items concerning the respondent's avoidance of the workplace or work-related anxiety.

    Time frame: Up to 31 months post baseline survey

  13. Ergonomic work environment

    Changes in self-reported ergonomic work environment between Time 0 and Time 1, and between Time 0 and Time 2. Ergonomic work environment is measured by 11 items concerning the respondent's physical tasks at work.

    Time frame: Up to 31 months post baseline survey

  14. Organisational change

    Changes in self-reported organisational change between Time 0 and Time 1, and between Time 0 and Time 2. Organisational change is part of the survey in the MBW intervention, and is measured using the 3 items covering changes in management, colleagues and tasks.

    Time frame: Up to 31 months post baseline survey

  15. Work/family conflict

    Changes in self-reported work/family conflict between Time 0 and Time 1, and between Time 0 and Time 2. Work/family conflict is part of the survey in the MBW intervention, and is measured using the 4 items with the highest factor loading in the Home-Work Interference Scale.

    Time frame: Up to 31 months post baseline survey

  16. Demand and control

    Changes in self-reported demand and control between Time 0 and Time 1, and between Time 0 and Time 2. Demand and control is measured using three questions from the instrument developed by Karasek/Theorell, and is part of the survey in the MBW intervention. A high score on either of the three items triggers the rest of the questionnaire.

    Time frame: Up to 31 months post baseline survey

07

Study locations

5 sites
  • Helse I Arbeid Nordlandssykehuset
    Bodø, Nordland 8092, Norway
  • Helse I Arbeid Helgelandssykehuset
    Sandnessjøen, Nordland 8800, Norway
  • Opptreningssenteret i Finnmark
    Alta, Troms Og Finnmark 9510, Norway
  • Helse I Arbeid Finnmarkssykehuset
    Kirkenes, Troms Og Finnmark 9915, Norway
  • Helse I Arbeid Universitetssykehuset Nord-Norge
    Tromsø, Troms Og Finnmark 9019, Norway
08

References and documents

Publications

  • Myhrer M, Brinchmann B, Trichet L, Aars NA, Mykletun A. Barriers for return to work as an iatrogenic effect of sickness absence: a proposed conceptual framework and questionnaire based on a cross-sectional study. BMC Public Health. 2026 Feb 12;26(1):920. doi: 10.1186/s12889-026-26584-1. PubMed 41680726 ↗
  • Bardal I, Aars NAP, Trichet LO, Brandseth OL, Terjesen C, Irgens E, Hansen BO, Kristoffersen A, Hoper A, Jenssen OR, Brinchmann B, Mykletun A. Expanding the Focus on Work Factors in an Outpatient Setting: Does a Nudge of Patients and Clinicians have an Effect on Return-to-Work and Benefits? Findings from the NSAC Nudge Multicentre Randomised Controlled Trial. J Occup Rehabil. 2025 Dec 12. doi: 10.1007/s10926-025-10343-x. Online ahead of print. PubMed 41385138 ↗
  • Aars NA, Bardal I, Brinchmann B, Mykletun A. Naturalistic trial of nudging patients and clinicians in the Norwegian sickness absence clinics: a study protocol for the NSAC Nudge Study. BMJ Open. 2025 Mar 3;15(3):e089758. doi: 10.1136/bmjopen-2024-089758. PubMed 40032398 ↗

Individual participant data

Plan to share: No — There are no plans to share individual patient data with other researchers. At the stage of analyses, associated researchers will be provided with an anonymized data set including all relevant data to answer the research questions.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Apr 2028, 79 months after the start.

Of 251 non-industry interventional studies with no phase under Musculoskeletal Diseases, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 38. This study's planned 79 months is above that.

Counting every sponsor, half of 266 studies reached it within 16 months; a quarter within 6 and three quarters within 36.

Musculoskeletal Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2021
First posted
Aug 16, 2021
StartActual
Sep 6, 2021
Primary completionEst.
Apr 12, 2028
CompletionEst.
Jan 12, 2033
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05006976
Lead sponsor
Nordlandssykehuset HF
Collaborators
University Hospital of North Norway, Opptreningssenteret i Finnmark (Alta, Norway), Helgeland Hospital Trust, Finnmarkssykehuset HF (Kirkenes, Norway), UiT The Arctic University of Norway
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Sep 6, 2021
Primary completion
Apr 12, 2028 (estimated)
Completion
Jan 12, 2033 (estimated)
Last update
Apr 13, 2026

Study contacts

Arnstein Mykletun, PhD
principal investigator · UiT The Arctic University of Norway

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion